NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

China legislation have asked the US Commerce Department to harden its policies around who can run clinical trials at sites ...

Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has ...

Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.